Source - GNW

Summit Therapeutics plc
("Summit", or the "Company")

Summit Therapeutics Files US Annual Report on Form 20-F

Oxford, UK, and Cambridge, MA, US, 13 April 2018 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT) provides notification that the Company has today filed its US Annual Report on Form 20-F for the year ended 31 January 2018 with the US Securities and Exchange Commission ("SEC").

The Form 20-F is available to download, either from the Investors section of the Company website at www.summitplc.com or from the SEC website at www.sec.gov.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit  
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)   +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson   
   
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer   
   
Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance   
Tom Salvesen, Corporate Broking   
   
MacDougall Biomedical Communications (US) Tel: +1 781 235 3060
Karen Sharma  [email protected]
   
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson /  [email protected]
Philippa Gardner   

-END-




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via Globenewswire